MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

[1]  V. Ntziachristos,et al.  Towards in vivo characterization of thyroid nodules suspicious for malignancy using multispectral optoacoustic tomography , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  P. V. van Diest,et al.  Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Maranghi,et al.  Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension? , 2021, Journal of clinical medicine.

[4]  R. V. van Ginkel,et al.  Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial , 2020, The Journal of Nuclear Medicine.

[5]  Yuxuan Qiu,et al.  Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis , 2020, Endocrine.

[6]  R. Netea-Maier,et al.  The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis , 2020, Journal of clinical medicine.

[7]  K. Schepman,et al.  Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery , 2020, Nature Communications.

[8]  Ming-gao Yu,et al.  Is ultrasonographic evaluation sensitive enough to detect multicentric papillary thyroid carcinoma? , 2020, Gland surgery.

[9]  S. Kruijff,et al.  Is less always more in a national well-differentiated thyroid cancer population? , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. Karrenbeld,et al.  The Optimal Imaging Window for Dysplastic Colorectal Polyp Detection Using c-Met–Targeted Fluorescence Molecular Endoscopy , 2020, The Journal of Nuclear Medicine.

[11]  K. Schepman,et al.  Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study , 2020, Theranostics.

[12]  V. Paleri,et al.  Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer , 2020, European Thyroid Journal.

[13]  Zhiyong Wu,et al.  Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer , 2019, Endocrine.

[14]  E. Cvejic,et al.  Health-Related Quality of Life After Diagnosis and Treatment of Differentiated Thyroid Cancer and Association With Type of Surgical Treatment , 2019, JAMA otolaryngology-- head & neck surgery.

[15]  Bert van der Vegt,et al.  Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers , 2018, Nature Communications.

[16]  Sun Wook Cho,et al.  Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) , 2018, Endocrinology and metabolism.

[17]  A. Miyauchi,et al.  Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients , 2018, World Journal of Surgery.

[18]  C. Larsson,et al.  A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis , 2017, BMC Cancer.

[19]  Vasilis Ntziachristos,et al.  In-vivo handheld optoacoustic tomography of the human thyroid , 2016, Photoacoustics.

[20]  J. Moalem,et al.  Preliminary results of ex vivo multispectral photoacoustic imaging in the management of thyroid cancer. , 2014, AJR. American journal of roentgenology.

[21]  P. Parker,et al.  Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways , 2014, Nature Communications.

[22]  B. Koo,et al.  Upregulation of HGF and c-MET is Associated with Subclinical Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma , 2014, Annals of Surgical Oncology.

[23]  H. Moon,et al.  Positive predictive value and interobserver variability of preoperative staging sonography for thyroid carcinoma. , 2011, AJR. American journal of roentgenology.

[24]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[25]  Z. Jehan,et al.  Genome‐wide expression analysis of Middle Eastern papillary thyroid cancer reveals c‐MET as a novel target for cancer therapy , 2007, The Journal of pathology.

[26]  A. Pasquini,et al.  Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid , 2004, The Journal of pathology.

[27]  C Eng,et al.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Lillehaug,et al.  Difference in Patterns of Met Expression in Papillary Thyroid Carcinomas and Nonneoplastic Thyroid Tissue , 2001, World Journal of Surgery.

[29]  A. Stoppacciaro,et al.  Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis , 2001, The Journal of pathology.

[30]  P. Comoglio,et al.  Expression of Met protein and urokinase‐type plasminogen activator receptor (uPA‐R) in papillary carcinoma of the thyroid , 1998, The Journal of pathology.

[31]  T. Nakajima,et al.  c‐Met expression of thyroid tissue with special reference to papillary carcinoma , 1998, Pathology international.

[32]  F. Trimarchi,et al.  Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. , 1998, Thyroid : official journal of the American Thyroid Association.

[33]  P. Comoglio,et al.  EXPRESSION OF Met PROTEIN IN THYROID TUMOURS , 1996, The Journal of pathology.

[34]  W. Birchmeier,et al.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells , 1993, The Journal of cell biology.

[35]  Sabrina S Wilson.  Radiology , 1938, Glasgow Medical Journal.

[36]  K. Devon,et al.  Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. , 2019, Surgery.